HIV HGP-30W vaccine - CEL-SCI

Drug Profile

HIV HGP-30W vaccine - CEL-SCI

Alternative Names: HGP-30; HGP-30W; HIV p17 vaccine

Latest Information Update: 28 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CEL-SCI Corporation
  • Developer AIDS Research Alliance; University of Nebraska Medical Center
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 28 Sep 2006 Discontinued - Phase-I for HIV infections treatment in United Kingdom (Injection)
  • 28 Sep 2006 Discontinued - Phase-II for HIV infections treatment in Netherlands (Injection)
  • 28 Sep 2006 Discontinued - Phase-II for HIV infections treatment in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top